Literature DB >> 977947

Inhibition of normal allogenic lymphocyte mitogenesis by a soluble inhibitor extracted from human colonic carcinoma.

M M Remacle-Bonnet, F J Pommier, S Kaplanski, R J Rance, R C Depieds.   

Abstract

Soluble extracts from human colonic tumors (STE) and from their hepatic metastases (SHME) were found to be unable to induce a proliferative response among normal allogenic lymphocytes. However, addition of these tissue extracts to cultures stimulated with various mitogens resulted in an almost complete inhibition of lymphocyte DNA synthesis. Nevertheless, they did not reduce the unstimulated lymphocyte spontaneous proliferation. Control experiments have shown that normal or nonmalignant tissues do not affect the lymphocyte reactivity to mitogens. The specific immunosuppressive evvect was found to be irreversible and to block lymphocyte activation at an early stage. The inhibitor was soluble (not sedimented at 220,000 times G for 2 hr) and not nonspecifically cytotoxic. STE was slso found to induce morphologic alterations resulting in blastlike cell production. However, no mitotic figures were seen, even after colchicin treatment. It is suggested that STE might contain molecular component(s) which would exert a double effect: 1) trigger metabolic alterations responsible for the blast-like cell induction, and 2) inhibit the lymphoproliferative response. The significance of such a mechanism is discussed in conection with the nonspecific immunosuppression caused by a tumor and the immune unresponsiveness against the tumor itself. A preliminiary characterization of this tumor material has shown that its molecular weight was about 70,000 and that it is not related to carcinoembryonic antigen or alpha-fetoprotein.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 977947

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Comparison of transforming growth factor beta and a human tumour-derived suppressor factor.

Authors:  S S Somers; J F Dye; P J Guillou
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.

Authors:  P J Guillou; P C Sedman; C W Ramsden
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 3.  Immunobiology of complete molar pregnancy and gestational trophoblastic tumor.

Authors:  R S Berkowitz; S A Umpierre; S Taylor-Emery; D P Goldstein; D J Anderson
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

4.  Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.

Authors:  S K Gregorian; J R Battisto
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.

Authors:  W M Mulder; M J Stukart; M Roos; R A van Lier; J Wagstaff; R J Scheper; E Bloemena
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

6.  Inhibition of lymphocyte mitogenesis by factor(s) released from macrophages isolated from ascitic fluid of advanced ovarian cancer patients.

Authors:  B Sheid; J Boyce
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: an immunohistological analysis.

Authors:  L Håkansson; G Adell; B Boeryd; F Sjögren; R Sjödahl
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.